Literature DB >> 34400447

Seroprevalence of COVID-19 IgG antibodies among healthcare workers of Pakistan: a cross-sectional study assessing exposure to COVID-19 and identification of high-risk subgroups.

Hijab Batool1, Omar Chughtai2, Muhammad Dilawar Khan3, Akhtar Sohail Chughtai2, Shakeel Ashraf2, Muhammad Jamil Khan2.   

Abstract

OBJECTIVE: In this study, we aimed to find the seroprevalence of healthcare workers (HCWs) of Pakistan involved in the treatment and care of patients with COVID-19.
SETTING: This was a cross-sectional study and total of 15 000 HCWs involved in providing services and care to the patients with COVID-19 were randomly selected from all over Pakistan. PARTICIPANTS: Informed consent was taken from all participants and were included according to inclusion and exclusion criteria. All testing was done on serum samples for the qualitative detection of SARS-CoV-2 IgG antibodies using Abbott Chemiluminescent microparticle immunoassay. An index of 1.4 was used as a cut-off to mark reactive and non-reactive cases. SPSS V.23.0 was used for data analysis. OUTCOME: Immune status of the study population depicting seroprevalence among HCWs.
RESULTS: Out of all the candidates, majority of the HCWs were men (61.9%) and were doctors (62.4%). The mean age of participants was 32.8 years (SD 8.7) and majority were asymptomatic (51.8%). In this study, 33% of the HCWs were reactive for SARS-CoV-2 IgG antibody. Around 44% of the reactive cases were asymptomatic. The symptoms more significantly associated with seropositivity were: fever (OR 1.31; 95% CI 1.16 to 1.48), headache (OR 2.43; 95% CI 2.16 to 2.73), cough and shortness of breath (OR 2.10; 95% CI 1.91 to 2.31), loss of sense of smell or taste (OR 3.70; 95% CI 3.29 to 4.17) (p<0.001). Factors which showed significant association with the presence of antibodies were professional category (absolute risk (AR) 0.09; OR 1.46; 95% CI 1.36 to 1.56), availability of protective masks (AR 0.02; OR 0.90; 95% CI 0.84 to 0.96), safety goggles (AR 0.02; OR 0.90; 95% CI 0.84 to 0.97) and living arrangements (AR 0.03; OR 1.12; 95% CI 1.04 to 1.20) (p<0.05).
CONCLUSION: Our study showed a high seropositivity of HCWs dealing with patients with COVID-19 in Pakistan revealing significant association with professional category, nature of work place and precautions taken while performing duties. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  chemical pathology; health & safety; infectious diseases; public health

Mesh:

Substances:

Year:  2021        PMID: 34400447      PMCID: PMC8370836          DOI: 10.1136/bmjopen-2020-046276

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


First study in the country to report seroprevalence of COVID-19 IgG among healthcare workers. Health policy makers can use the findings of our study to make better strategies. High-risk subgroups of healthcare workers and high-risk health departments were identified. Only the antibody against the N protein of SARS-CoV-2 was assessed. Subjects were not followed up to understand the duration of seropositivity.

Introduction

COVID-19 associated with SARS-CoV-2 has emerged as a pandemic. Since the identification of initial cases of this atypical pneumonia, there has been an exponential increase in the number of cases worldwide.1 Some of the few causes of this exponential increase in number include high-transmission rate especially among the asymptomatic cases, poor healthcare strategies and limited knowledge about the COVID-19.2 Subclinical or asymptomatic cases are one of the major challenges in this pandemic as it is presumed that these cases can play a major role in infection spread while remaining undiscovered in the community. As of 22 August 2020, confirmed cases of COVID-19 in Pakistan are 292 150 with 731 critical cases and 275 317 recoveries.3 The correct estimate of the spread of COVID-19 in Pakistan is still not clear, posing a huge challenge to healthcare agencies of Pakistan. Most of the mildly symptomatic, asymptomatic cases and the cases belonging to areas of limited resources who are not tested via government healthcare agencies can easily be missed and the actual number of the affected individuals remains unidentified. The risk of COVID-19 among healthcare workers (HCWs) of Pakistan is still not clear. Studies have revealed that 9% of the individuals in Italy and 26% of the individuals in Spain who were tested positive for COVID-19 via reverse transcriptase PCR (RT-PCR) in prevalence studies were HCWs.4 5 In accordance with other coronaviruses, HCWs-associated transmission of COVID-19 appears to play a major role in infection spread. One prevalence study suggested that more than 40% of the diagnosed cases of COVID-19 were assumed to have been acquired from HCWs.6 Majority of the SARS-CoV-2 infected cases remain asymptomatic and the virus may be far more widely distributed than experts may believe.7 During the first 21 days of SARS-CoV-2 infection, reasonable increases are observed in virus-specific IgM and IgG titers.8 According to one estimate, herd immunity can be ensured if around 50%–67% of the population develops immunity against SARS-CoV-2.9 Seroconversion is determined by analysing antibody status of the population.9 10 Serosurveillance of HCWs is an important indicator of COVID-19 spread as they fall in the category of population which is most exposed to SARS-CoV-2 infection. In this study, we aimed to find the seroprevalence of HCWs of Pakistan involved in the management and care of patients with COVID-19. This study will help to identify the high-risk subgroups of HCWs, high-risk departments and different factors associated with the risk of SARS-CoV-2 infection.

Methodology

Subject selection

A total of 15 000 HCWs both men and women were randomly selected for this study from all over Pakistan. A list of healthcare centres who were authorised to treat and diagnose patients with COVID-19 was issued by government officials of Pakistan and only the HCWs involved in providing services and care in these centres were involved in this study. All doctors, nurses/para medical staff and medical laboratory technologists in Pakistan are registered in Pakistan Medical Council health registry, Pakistan Nursing Council and Medical Laboratory Technology Association of Pakistan, respectively. The registration number of all healthcare professionals was confirmed from the authorities before including them in the study. The HCWs with no interaction with patients with COVID-19 (either direct contact or dealing with patient samples) or the workers who were not present on duty in the last one month from the date of commencement of study were excluded. Moreover, HCWs who were already involved in some clinical trials of COVID-19 were not involved in the study. All participants were explained the objective of the study and the HCWs showing active signs and symptoms compatible with COVID-19 were not involved in the study as they might be a risk to the team members of the laboratory taking samples and most probably be in the initial phase of the infection in which IgG is not likely to be present. After taking a written informed consent, the participants were asked to fill a questionnaire in which they had to mention their age, gender, professional category, place and nature of duty, kind of personal protective equipment (PPE) provided to them, presence of sign and symptoms and living arrangement. A 3 mL random blood sample was collected from each participant to assess immunological response. Sample was collected by trained phlebotomist wearing appropriate PPE. Our laboratory centres are located throughout the country; therefore, our own designated sample collection team was sent to collect samples from all the participants. No local occupational health nurses were involved in sample collection. All the samples collected were transported immediately to the laboratory where those were centrifuged at 5000g for 5 min to separate sera for analysis.

Patient and public involvement

HCWs involved in providing services and care to the patients with COVID-19 were involved in the design and conduct of this study. Discussion sessions were arranged with a group of HCWs to discuss the feasibility of the project, designing proforma, outcome measures and sample collection procedure. This discussion group considered participants’ priorities and preferences while designing the study. All the participants will be informed about the results of the study after publication through phone calls and lab reports posted if desired by the study participants.

Laboratory analysis

Analysis was done on serum samples for the qualitative detection of SARS-CoV-2 IgG antibodies using Food and Drug Administration (FDA) approved Abbott Chemiluminescent Microparticle Immunoassay on Abbott Alinity Ci. This is an Emergency Use Authorization-granted assay with a specificity of 99.6% and sensitivity of 96.7% for COVID-19 confirmed cases with more than 14 days of symptoms. An index of 1.4 was used as a cut-off to mark reactive and non-reactive cases. Cases with results greater than the cut-off value were marked as reactive and those with results less than the cut-off were declared as non-reactive for SARS-CoV-2 IgG antibodies.

Statistical analysis

SPSS V.23.0 was used for data analysis. Seroprevalence was calculated and associations between variables of the study were tested via χ2 and Fisher’s exact test using p value <0.05 as significant. Relative risk was expressed as OR.

Results

Baseline characteristics of the participants

A total of 16 882 HCWs were randomly approached for the survey between 1 July 2020 and 20 July 2020. Of these, 1672 were excluded from the survey on the basis of exclusion criteria, 210 fulfilled the inclusion criteria but refused to participate and 15 000 cases were selected with a total participation rate of 88.8%. These HCWs included doctors, nurses and paramedical staff directly involved in providing medical care to the patients with COVID-19. Out of all the cases, majority of the HCWs were men (61.9%) and were doctors (62.4%) followed by paramedical staff (22%). The mean age of participants was 32.8 years±8.7 and majority were asymptomatic (51.8%). The nature of PPE provided to HCWs, the place of duty, living arrangements along with some other characteristics of the participating HCWs are mentioned in table 1.
Table 1

Baseline characteristics of healthcare workers participating in the study

GroupsSubgroupsTotal numberPercentages
GenderMale928261.9
Female571838.1
Age (years)Mean 32.8±8.7
CategoryDoctor936262.4
Nurse226015.1
Paramedics337822.5
Place of dutyGeneral ward632742.2
OPD/clinic401026.7
COVID-19 quarantine centre2911.9
COVID-19 isolation ward282018.8
HDU/ICU14459.6
Emergency unit320.2
Laboratory320.2
Operation theatre430.3
Tyvek suitsNot available778451.9
Available721648.1
Face shieldNot available951863.5
Available548236.5
Safety gogglesNot available10 29968.7
Available470131.3
GlovesNot available384925.7
Available11 15174.3
N95 masksNot available651443.4
Available848656.6
Surgical masksNot available414927.7
Available10 85172.3
Asymptomatic776851.8
Reported COVID-19 compatible symptoms within last 2 months626041.7
Experienced generalised fatigue only9726.5
Living arrangementLiving in hostel/single family608940.5
Living with family891159.5

HDU, High Dependency Unit; ICU, intensive care unit; OPD, Out Patient Department.

Baseline characteristics of healthcare workers participating in the study HDU, High Dependency Unit; ICU, intensive care unit; OPD, Out Patient Department.

Seroprevalence of SARS-CoV-2 IgG antibodies among the HCWs

In this study, 33% of the HCWs were reactive for SARS-CoV-2 IgG antibody and maximum percentage of HCWs (46%) showing seropositivity was between 23 and 30 years of age. Out of all the tests conducted, maximum number of participants were from Punjab (10 943) followed by Khyber Pakhtunkhwa (2606) (figure 1). City wise seropositivity is given in figure 2. Among the reactive cases, 40% of the HCWs performed duties in general COVID-19 ward, 28% were working in outpatient department receiving patients with COVID-19, 20% in COVID-19 isolation and quarantine centres and 10% were working in COVID-19 high dependency units with patients having severe symptoms requiring mechanical respiratory support.
Figure 1

Total number of tests conducted in each Province of Pakistan and respective seropositivity.

Figure 2

Seropositivity of healthcare workers in different cities of Pakistan.

Total number of tests conducted in each Province of Pakistan and respective seropositivity. Seropositivity of healthcare workers in different cities of Pakistan. Around 2223 (44%) of the reactive cases were asymptomatic. The symptoms more significantly associated with seropositivity were: low grade fever only (OR 1.31; 95% CI 1.16 to 1.48), high grade fever with headache (OR 2.43; 95% CI 2.16 to 2.73), fever with cough and shortness of breath (OR 2.10; 95% CI 1.91 to 2.31), Loss of sense of smell or taste only (OR 3.70; 95% CI 3.29 to 4.17) (p<0.001). Factors which showed significant association with the presence of antibodies were gender, professional category, availability of protective masks, safety goggles and living arrangements (p<0.05). Absolute risk (AR) and relative risk of different variables expressed in terms of OR are given in table 2.
Table 2

Factor analysis of different variables associated with seropositivity

GroupsSubgroupsNon-reactiveReactiveP valueOR95% CIARRR
GenderMale*6117 (41%)3165 (21%)<0.0010.870.81 to 0.940.030.91
Female3933 (26%)1785 (12%)
CategoryDoctor*6572 (44%)2790 (19%)<0.0011.4631.365 to 1.5680.091.31
Nurse1409 (9%)851 (6%)
Paramedics2069 (14%)1309 (8%)
Place of dutyGeneral ward/Isolation centres/operation theatre/lab*9100 (61%)4455 (30%)0.2851.0640.949 to 1.1930.021.06
HDU/ICU950 (6%)495 (3%)
Tyvek suitsNot available*5184 (34%)2600 (17%)0.270.9630.89 to 1.030.010.96
Available4866 (33%)2350 (16%)
Face sheildNot available*6331 (42%)3190 (21%)0.0830.930.875 to 1.000.010.93
Available3719 (25%)1760 (12%)
Safety gogglesNot available*6829 (45%)3470 (24%)0.0080.9040.84 to 0.970.020.93
Available3221 (21%)1480 (10%)
GlovesNot available*2592 (18%)1257 (8%)0.6011.0210.944 to 1.1040.011.03
Available7458 (50%)3693 (24%)
N95 masksNot available*4280 (29%)2234 (15%)0.0030.9020.842 to 0.9660.020.94
Available5770 (38%)2716 (18%)
Surgical masksNot available*2812 (19%)1337 (9%)0.2121.0500.973 to 1.1330.011.03
Available7238 (48%)3613 (24%)
Asymptomatic*5545 (37%)2223 (15%)<0.0011.5101.410 to 1.6170.091.32
Reported COVID-19 compatible symptoms within last 2 months4505 (30%)2727 (18%)
Living arrangementLiving alone/single family*4173 (27%)1916 (13%)0.0011.1241.049 to 1.2050.031.09
Living with joint family5877 (39%)3034 (21%)

*The reference group for the OR is the first mentioned group.

AR, absolute risk; HDU, High Dependency Unit; RR, relative risk.

Factor analysis of different variables associated with seropositivity *The reference group for the OR is the first mentioned group. AR, absolute risk; HDU, High Dependency Unit; RR, relative risk.

Discussion

Serosurveys are essential in the management of infectious diseases to assess the immunity in a population.11 This is the first study reporting SARS-CoV-2 IgG antibodies seroprevalence among HCWs in Pakistan who are the frontline warriors in this pandemic. Pakistan is a developing nation with limited medical resources and HCWs are not provided with all the necessary equipment to protect themselves from this deadly virus. In this study, we found a seropositivity of 33% among HCWs of Pakistan with highest seropositivity in the Punjab region of Pakistan with maximum disease burden.3 The association of antibodies with virus neutralisation, correlation of antibody titers with protection against re-infection and difference in immunological response of symptomatic and asymptomatic cases is still unclear.12 However, the role of serological assays in assessing the prevalence of COVID-19 in the community is unquestionable.13 We designed this study to investigate seroprevalence of SARS-CoV-2 IgG antibodies among the population involved in direct dealing with patients with COVID-19 (either the patients or direct dealing with patient samples) with FDA-approved assay having high analytical performance capable to identify IgG antibodies against N protein of the virus.14 The HCWs showing active signs and symptoms were excluded from the study to reduce the risk of exposure of laboratory staff collecting blood samples and also due to the probability of HCWs being present in acute phase of the infection when IgG is not developed enough to be detected by the assay. Given the fact that HCWs are at a very high risk of COVID-19, from our findings with a seropositivity of 33% among HCWs, it can be assumed that Pakistani population is still far from reaching more than 60% herd immunity level that is required for community protection against the infection.15 Low OR of some of the PPE (like protective masks) might be due to the fact that despite of existence, the PPE was not being used properly or they were not available in adequate quantity. To date, many studies have been conducted worldwide to unfold prevalence of SARS-CoV-2 IgG antibodies among HCWs. Screening of symptomatic HCWs has been done with the help of RT-PCR in some surveillance studies and it was found that almost 18% of the HCWs were infected by SARS-CoV-2.16 17 Another screening study on asymptomatic HCWs revealed that 3% of the staff was SARS-CoV-2 positive by RT-PCR.18 In one study, the authors speculated that frontline HCWs are more prone to be infected by the virus. Not only the health professionals who are working in the dedicated COVID-19 health facilities are expected to be exposed but also the workers who are performing duties in other specialties where patients with SARS-CoV-2 are admitted for other reasons.19 A study conducted on women admitted in labour room to give birth showed that 15% of the expecting mothers were SARS-CoV-2 positive and another study in old care home revealed 4% of the residents to be positive.20 21 A recent seroprevalence study conducted in Denmark showed that 4% of the HCWs showed seropositivity against SARS-CoV-2 and the risk of viral infection was related to the level of exposure to the infected patients.22 This study also revealed that seroconversion was higher in male HCWs as compared with female HCWs but the authors attributed this finding to higher frequency of critical illness in men rather than higher susceptibility of infection in male gender.22 This finding is in accordance with our study in which male HCWs showed more frequent seroconversion as compared with female HCWs and seropositivity had an association with direct contact with the patients. An Italian study found that 4.6% of the HCWs were seropositive, majority were men and low prevalence was found in asymptomatic cases.23 All these findings are in accordance with our study which yielded similar findings. Another study conducted at a large Spanish hospital found a seroprevalence of 9.3% in a random sample of healthcare professionals and the authors concluded that HCWs are at a higher risk to acquire SARS-CoV-2 infection from fellow workers or directly from the patients.24 Our study revealed that there is a significant association between presence and absence of PPE and seropositivity. Some studies suggest that seropositivity is attributable to institutional application of proper PPE use hospitals which prepared well before time for this pandemic had a lower infection rate among their HCWs.23 A special communication regarding risk assessment of HCWs performing duties at high-risk areas suggested that lack of understanding of the disease course, improper use of PPE, stress at work, unavailability of screening tests and lack of resources are the major factors leading to high rate of infection among this cohort.25 Our study has some limitations like only the antibody against the N protein was assessed, subjects were not followed up to understand the duration of seropositivity and protection from getting re-infected again.

Conclusion

This is a large-scale study conducted in all provinces of Pakistan showing a high seropositivity of HCWs dealing with patients with COVID-19. The seropositivity had significant association with place of duty, professional category and availability of PPE. This study can help healthcare policy makers of Pakistan to make better strategies to protect the frontline warriors in this pandemic. Subclinical or asymptomatic cases can play a major role in SARS-CoV-2 transmission while remaining undiscovered in the community. HCWs fall in the category of population which is most exposed to SARS-CoV-2 infection. 33% of the HCWs were reactive for SARS-CoV-2 IgG antibody and 44% of the reactive cases were asymptomatic Our study revealed that there is a significant association between use of personal protective equipment, professional category, place of duty and seropositivity. This study can help healthcare policy makers of Pakistan to know to extent of infection among the HCWs and make better strategies.
  23 in total

1.  Herd Immunity and Implications for SARS-CoV-2 Control.

Authors:  Saad B Omer; Inci Yildirim; Howard P Forman
Journal:  JAMA       Date:  2020-11-24       Impact factor: 56.272

2.  Antibody responses to SARS-CoV-2 in patients with COVID-19.

Authors:  Quan-Xin Long; Bai-Zhong Liu; Hai-Jun Deng; Gui-Cheng Wu; Kun Deng; Yao-Kai Chen; Pu Liao; Jing-Fu Qiu; Yong Lin; Xue-Fei Cai; De-Qiang Wang; Yuan Hu; Ji-Hua Ren; Ni Tang; Yin-Yin Xu; Li-Hua Yu; Zhan Mo; Fang Gong; Xiao-Li Zhang; Wen-Guang Tian; Li Hu; Xian-Xiang Zhang; Jiang-Lin Xiang; Hong-Xin Du; Hua-Wen Liu; Chun-Hui Lang; Xiao-He Luo; Shao-Bo Wu; Xiao-Ping Cui; Zheng Zhou; Man-Man Zhu; Jing Wang; Cheng-Jun Xue; Xiao-Feng Li; Li Wang; Zhi-Jie Li; Kun Wang; Chang-Chun Niu; Qing-Jun Yang; Xiao-Jun Tang; Yong Zhang; Xia-Mao Liu; Jin-Jing Li; De-Chun Zhang; Fan Zhang; Ping Liu; Jun Yuan; Qin Li; Jie-Li Hu; Juan Chen; Ai-Long Huang
Journal:  Nat Med       Date:  2020-04-29       Impact factor: 53.440

3.  Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital.

Authors:  Alberto L Garcia-Basteiro; Gemma Moncunill; Marta Tortajada; Marta Vidal; Caterina Guinovart; Alfons Jiménez; Rebeca Santano; Sergi Sanz; Susana Méndez; Anna Llupià; Ruth Aguilar; Selena Alonso; Diana Barrios; Carlo Carolis; Pau Cisteró; Eugenia Chóliz; Angeline Cruz; Silvia Fochs; Chenjerai Jairoce; Jochen Hecht; Montserrat Lamoglia; Mikel J Martínez; Robert A Mitchell; Natalia Ortega; Nuria Pey; Laura Puyol; Marta Ribes; Neus Rosell; Patricia Sotomayor; Sara Torres; Sarah Williams; Sonia Barroso; Anna Vilella; José Muñoz; Antoni Trilla; Pilar Varela; Alfredo Mayor; Carlota Dobaño
Journal:  Nat Commun       Date:  2020-07-08       Impact factor: 14.919

4.  Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho.

Authors:  Andrew Bryan; Gregory Pepper; Mark H Wener; Susan L Fink; Chihiro Morishima; Anu Chaudhary; Keith R Jerome; Patrick C Mathias; Alexander L Greninger
Journal:  J Clin Microbiol       Date:  2020-07-23       Impact factor: 5.948

5.  Double-Edged Spike.

Authors:  Richard Torres; Henry M Rinder
Journal:  Am J Clin Pathol       Date:  2020-05-05       Impact factor: 2.493

6.  Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission.

Authors:  Lucy Rivett; Sushmita Sridhar; Dominic Sparkes; Matthew Routledge; Nick K Jones; Ian G Goodfellow; Stephen Baker; Michael P Weekes; Sally Forrest; Jamie Young; Joana Pereira-Dias; William L Hamilton; Mark Ferris; M Estee Torok; Luke Meredith; Martin D Curran; Stewart Fuller; Afzal Chaudhry; Ashley Shaw; Richard J Samworth; John R Bradley; Gordon Dougan; Kenneth Gc Smith; Paul J Lehner; Nicholas J Matheson; Giles Wright
Journal:  Elife       Date:  2020-05-11       Impact factor: 8.140

7.  Risk of COVID-19 in health-care workers in Denmark: an observational cohort study.

Authors:  Kasper Iversen; Henning Bundgaard; Rasmus B Hasselbalch; Jonas H Kristensen; Pernille B Nielsen; Mia Pries-Heje; Andreas D Knudsen; Casper E Christensen; Kamille Fogh; Jakob B Norsk; Ove Andersen; Thea K Fischer; Claus Antonio Juul Jensen; Margit Larsen; Christian Torp-Pedersen; Jørgen Rungby; Sisse B Ditlev; Ida Hageman; Rasmus Møgelvang; Christoffer E Hother; Mikkel Gybel-Brask; Erik Sørensen; Lene Harritshøj; Fredrik Folke; Curt Sten; Thomas Benfield; Susanne Dam Nielsen; Henrik Ullum
Journal:  Lancet Infect Dis       Date:  2020-08-03       Impact factor: 25.071

8.  Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries.

Authors:  Kin On Kwok; Florence Lai; Wan In Wei; Samuel Yeung Shan Wong; Julian W T Tang
Journal:  J Infect       Date:  2020-03-21       Impact factor: 6.072

Review 9.  COVID-19 and Italy: what next?

Authors:  Andrea Remuzzi; Giuseppe Remuzzi
Journal:  Lancet       Date:  2020-03-13       Impact factor: 79.321

10.  Roll-out of SARS-CoV-2 testing for healthcare workers at a large NHS Foundation Trust in the United Kingdom, March 2020.

Authors:  Alexander J Keeley; Cariad Evans; Hayley Colton; Michael Ankcorn; Alison Cope; Amy State; Tracy Bennett; Prosenjit Giri; Thushan I de Silva; Mohammad Raza
Journal:  Euro Surveill       Date:  2020-04
View more
  2 in total

1.  Seroprevalence of Sars-Cov-2 antibodies among eligible blood donors of Peshawar, Pakistan.

Authors:  Muhammad Nisar Khan; Haleema Khan; Muhammad Shahzad; Muhammad Ibrahim; Muhammad Arif; Zeeshan Kibria; Usman Waheed; Noore Saba; Inayat Shah; Yasar Mehmood Yousafzai
Journal:  Am J Blood Res       Date:  2022-06-20

2.  Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.

Authors:  Zhenxiao Ren; Mitsuhiro Nishimura; Lidya Handayani Tjan; Koichi Furukawa; Yukiya Kurahashi; Silvia Sutandhio; Kaito Aoki; Natsumi Hasegawa; Jun Arii; Kenichi Uto; Keiji Matsui; Itsuko Sato; Jun Saegusa; Nonoka Godai; Kohei Takeshita; Masaki Yamamoto; Tatsuya Nagashima; Yasuko Mori
Journal:  PLoS One       Date:  2022-04-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.